Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Inflammation in Atherosclerosis: From Pathophysiology.

Slides:



Advertisements
Similar presentations
Prognostic Utility of Secretory Phospholipase A 2 in Patients with Stable Coronary Artery Disease M. O'Donoghue, Z. Mallat, D.A. Morrow, J. Benessiano,
Advertisements

Immune System Overview. GOT DEFENSE? ANATOMY OF THE IMMUNE SYSTEM The immune system is localized in several parts of the body –immune cells develop.
atherosclerosis Jon Yap John A. Burns School of Medicine
Dental Microbiology #211 IMMUNOLOGY Lecture 2. Topics The B and T Lymphocytes Antigen-specific Receptors on B and T cells CD4+ and CD8+ T cells Cytokines.
Overview on Immunology and Introduction to Innate Immunity
Ridker PM, et al. Lancet 2009;373: Baseline clinical characteristics of the study population in the placebo and rosuvastatin groups according.
Cytokines Concept Characteristics Classification Biologic activity
Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Does Elevated C-Reactive Protein Increase Atrial.
Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2013 ACC/AHA Guideline on the Treatment of Blood.
Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Omega-3 Polyunsaturated Fatty Acids and Cardiovascular.
Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: A Novel Inhibitory Effect of Naloxone on Macrophage.
Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Primary Prevention With Statins: ACC/AHA Risk-Based.
Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Safety and Efficacy of Low Blood Pressures Among.
Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Mycophenolate Mofetil Decreases Atherosclerotic Lesion.
J Am Coll Cardiol. 2015;65(24): doi: /j.jacc Figure Legend:
Date of download: 6/2/2016 Copyright © The American College of Cardiology. All rights reserved. From: The impact of plasma levels of C-reactive protein,
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Lipid Profile, Plasma Apolipoproteins, and Risk of.
Date of download: 6/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Calf Muscle Characteristics, Strength Measures, and.
Date of download: 6/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Major Lipids, Apolipoproteins, and Risk of Vascular.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Multifaceted Clinical Readouts of Platelet Inhibition.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Haptoglobin Genotype Is a Consistent Marker of Coronary.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Effectiveness of Pharmacist Interventions on.
Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: Pregnancy-associated plasma protein-A levels in.
Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: Genetic Inhibition of CETP, Ischemic Vascular Disease.
Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: An Endocrine Genetic Signal Between Blood Cells.
Date of download: 6/23/2016 From: Glucocorticoid Therapy for Immune-Mediated Diseases: Basic and Clinical Correlates Ann Intern Med. 1993;119(12):
Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Implications of Introducing High-Sensitivity Cardiac.
Date of download: 6/26/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Cost-Effectiveness of C-Reactive Protein Testing.
Date of download: 6/26/2016 Copyright © The American College of Cardiology. All rights reserved. From: Plasma triglycerides and type III hyperlipidemia.
Date of download: 6/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Cardio-Pulmonary-Renal Interactions: A Multidisciplinary.
Date of download: 6/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: A Test in Context: High-Sensitivity C-Reactive Protein.
Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: A Proposal to Incorporate Trial Data Into a Hybrid.
Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Amyloid-Beta (1-40) and the Risk of Death From Cardiovascular.
Date of download: 7/2/2016 Copyright © The American College of Cardiology. All rights reserved. From: Heavy Metals, Cardiovascular Disease, and the Unexpected.
Date of download: 7/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Oxidation-Specific Biomarkers, Prospective 15-Year.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Comparative effects of AT1-antagonism and angiotensin-converting.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Randomized Trial of Paclitaxel- Versus Sirolimus-Eluting.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Atherothrombosis J Am Coll Cardiol. 2012;60(10):
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Modified Serum Profiles of Inflammatory and Vasoconstrictive.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Usual Blood Pressure and Risk of New-Onset Diabetes:
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:
Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: Pharmacologic plaque passivation for the reduction.
Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: Potential Impact of Time Trend of Life-Style Factors.
From: High-Density Lipoprotein Cholesterol and Particle Concentrations, Carotid Atherosclerosis, and Coronary Events: MESA (Multi-Ethnic Study of Atherosclerosis)
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Incidence and Correlates of Drug-Eluting Stent Thrombosis.
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Nonfasting Glucose, Ischemic Heart Disease, and.
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Implications of Coronary Artery Calcium Testing.
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Next Steps in Primary Prevention of Coronary Heart.
Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Glycated Hemoglobin Measurement and Prediction of.
From: Genetic Inhibition of CETP, Ischemic Vascular Disease and Mortality, and Possible Adverse Effects J Am Coll Cardiol. 2012;60(20): doi: /j.jacc
M1 – Immunology CYTOKINES AND CHEMOKINES March 26, 2009 Ronald B
Peter Libby, MD  The American Journal of Medicine 
Copyright © 2009 American Medical Association. All rights reserved.
Copyright © 2014 American Medical Association. All rights reserved.
GENERAL IMMUNOLOGY PHT 324
Mononuclear phagocytes in Immune Defence
Copyright © 2007 American Medical Association. All rights reserved.
Copyright © 2012 American Medical Association. All rights reserved.
Cardiovascular Risk and Psoriasis: Beyond the Traditional Risk Factors
Phagocytic Cells = cells that
The role of viruses in acute exacerbations of asthma
OR (95% CI) for CHD associated with inflammatory markers before and after adjustment for established risk factors. OR (95% CI) for CHD associated with.
Figure 1 Diagram showing analysis flow of patient selection and treatment allocation of ONTARGET/TRANSCEND. Figure 1 Diagram showing analysis flow of patient.
OR (95% CI) for CHD associated with inflammatory markers in all participants and in subsets of non-users of statins or non-users of aspirin therapy. OR.
Baseline Characteristics of the Subjects*
Monocyte-Macrophages and T Cells in Atherosclerosis
Lec.9 Cytokines.
Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm
Macrophages in the Pathogenesis of Atherosclerosis
Atherosclerosis  Christopher K. Glass, Joseph L. Witztum  Cell 
Presentation transcript:

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Inflammation in Atherosclerosis: From Pathophysiology to Practice J Am Coll Cardiol. 2009;54(23): doi: /j.jacc Elements Involved in Innate Immunity This figure summarizes some of the functions ascribed to various cellular participants in atherosclerosis that may participate in the disease and its complication when dysregulated. Mononuclear phagocytes represent the bulwark of the innate immune defenses in mammals. Monocytes give rise to macrophages, which in the arterial intima form foam cells, the hallmark of the arterial fatty streak. Recent work has focused on heterogeneity of mononuclear phagocytes. We now recognize a proinflammatory subset distinct from a less inflammatory population of monocytes. The inflammatory subset expresses high levels of the cell-surface marker Ly6C (also known as GR-1) in the mouse. These inflammatory monocytes express higher levels of Toll-like receptors (TLR), and the other functions indicated, including elaboration of high levels of the cytokines tumor necrosis factor (TNF) and interleukin (IL)-1. The less inflammatory subset of monocytes express higher levels of transforming growth factor (TGF)-beta, the scavenger receptors CD36 and scavenger receptor A (SR-A), and angiogenic mediators including vascular endothelial growth factor (VEGF). Dendritic cells express human leukocyte antigen (HLA) molecules among the other indicated structures. Dendritic cells present antigens to T cells, linking innate to adaptive immunity. Mast cells elaborate many mediators as shown. Recent data support a causal role for mast cells in mouse atherosclerosis. Platelets also participate in adaptive immunity. When activated, platelets exteriorize CD40 ligand (CD40L or CD154) and release mediators including RANTES (regulated and T-cell expressed secreted), myeloid related protein (MRP)-8/14, platelet-derived growth factor (PDGF), and TGF-beta. Figure Legend:

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Inflammation in Atherosclerosis: From Pathophysiology to Practice J Am Coll Cardiol. 2009;54(23): doi: /j.jacc Cells Involved in Atherosclerosis Express Pattern-Recognition Receptors Involved in Innate Immunity With the cooperation of CD14, Toll-like receptor (TLR) 4 binds bacterial lipopolysaccharides (LPS) and a variety of other potential instigators of inflammation and atherosclerosis including heat shock proteins (hsp). TLR2 usually exists as a heterodimer with TLR1 or TLR6. TLR2 complexes can bind microbial products as shown and, in addition, apolipoprotein CIII (Apo CIII). Scavenger receptor A binds modified low-density lipoproteins (LDL). CD36 binds oxidatively modified LDL. The receptor for advanced glycation endproducts (RAGE) also decorates many cells involved in atherosclerosis and may function in inflammatory signaling. Figure Legend:

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Inflammation in Atherosclerosis: From Pathophysiology to Practice J Am Coll Cardiol. 2009;54(23): doi: /j.jacc Cells Involved in Adaptive Immunity The text describes the functional roles of the 5 classes of lymphocytes depicted in atherosclerosis. B cells elaborate antibodies (Ab). A specialized subset of B cells (B1 cells) elaborate primarily immunoglobulin M antibodies, including natural antibodies that recognize constituents of oxidized low-density lipoprotein (oxLDL). The bottom panel of this figure portrays diagrammatically the effect of the various cell types on lesions, based mostly on experiments in mice. Up arrows indicate aggravation of lesion formation. Down arrows indicate reduction in lesion formation. This diagram summarizes the “net” effect attributed to the cell type on atherosclerosis primarily on the basis of experiments in mice. In some cases, this figure necessarily oversimplifies the complexity of the data. For example, not all TH 2 cell functions and not all antibodies elaborated by B cells may mitigate atherogenesis. CTL = cytolytic T lymphocytes; IFN = interferon; hsp = heat shock protein; Th = T helper cells; T Reg = regulatory T cells; other abbreviations as in Figure 1. Figure Legend:

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Inflammation in Atherosclerosis: From Pathophysiology to Practice J Am Coll Cardiol. 2009;54(23): doi: /j.jacc Cumulative Incidence of Cardiovascular Events in the JUPITER Trial, According to the JUPITER Study Group A shows the cumulative incidence of the primary end point (nonfatal myocardial infarction, nonfatal stroke, arterial revascularization, hospitalization for unstable angina, or confirmed death from a cardiovascular cause). B shows the cumulative incidence of nonfatal myocardial infarction, nonfatal stroke, or confirmed death from a cardiovascular cause. C shows cumulative incidence for arterial revascularization or hospitalization for unstable angina. D shows the cumulative incidence of death from any cause. Figure Legend:

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Inflammation in Atherosclerosis: From Pathophysiology to Practice J Am Coll Cardiol. 2009;54(23): doi: /j.jacc Hazard Ratios for Incident Cardiovascular Events in the JUPITER Trial According to Achieved Concentrations of LDL Cholesterol and hsCRP After Initiation of Rosuvastatin Therapy Data were adjusted for age, baseline low-density lipoprotein (LDL) and high-density lipoprotein cholesterol, baseline high-sensitivity C-reactive protein (hsCRP), blood pressure, sex, body mass index, smoking status, and parental history of premature coronary heart disease. Event rates are per 100 person-years. p < Figure Legend:

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Inflammation in Atherosclerosis: From Pathophysiology to Practice J Am Coll Cardiol. 2009;54(23): doi: /j.jacc Effects of Rosuvastatin on the Primary Trial End Point, According to Baseline Characteristics of the JUPITER Cohort Figure Legend: